西地那非与波生坦治疗先天性心脏病介入术后合并中重度肺动脉高压效果比较  

Clinical Observation of Sildenafil and Bosentan in the Treatment of CHD with Moderate to Severe PAH

作　　者：苏坤 SU Kun(Enshi Hualong General Hospital,Enshi Hubei 445000,China)

机构地区：[1]恩施华龙总医院,湖北恩施445000

出　　处：《药品评价》2021年第21期1333-1335,共3页Drug Evaluation

摘　　要：目的:西地那非与波生坦治疗先天性心脏病(CHD)介入术后合并中重度肺动脉高压(PAH)的临床观察。方法:选取恩施华龙总医院2019年8月至2020年9月收治的80例CHD介入术后合并中重度 PAH患者作为研究对象,按照随机数字表法分为对照组(n=40,予以西地那非治疗)和观察组(n=40,予以波生坦治疗),两组在基础治疗的基础上,观察不同给药后患者的心功能、6 min步行试验(6MWT)及肺功能指标的变化。结果:治疗后,两组左室舒张末期内径(LVEDd)表达水平下降,观察组低于对照组,左室收缩末期内径(LVESd)及左室射血分数(LVEF)表达水平上升,观察组高于对照组(P<0.05);观察组6MWT高于对照组(P<0.05);观察组肺功能[肺活量(VC)、第1秒用力呼吸量与用力肺活量的比值(FEV1/FVC)、最大通气量(MVV)]高于对照组(P<0.05)。结论:对于CHD介入术后合并中重度 PAH患者使用波生坦治疗,可改善心肺功能,提高心脏耐受力。Objective:To investigate the clinical observation of sildenafil and bosentan in the treatment of congenital heart disease (CHD) combined with moderate to severe pulmonary hypertension (PAH) after intervention.Methods:Selected 80 patients with moderate to severe PAH after CHD interventional operation in Enshi Hualong General Hospital from August 2019 to September 2020 as the research objects,and divided them into the control group (n=40,given sildenafil treatment) and observation group (n=40,treated with bosentan) according to the random number table method.On the basis of basic treatment,the heart function,6-minute walk test (6MWT),and lung function indexes of the two groups of patients were observed after different administrations.Results:After treatment,the left ventricular end diastolic diameter (LVEDd) of the two groups of patients decreased,the observation group was lower than the control group,the left ventricular end systolic diameter (LVESD) and left ventricular ejection fraction (LVEF) expression levels increased,and the observation group was higher than the control group (P<0.05);the 6MWT of the observation group was significantly higher than that of the control group (P<0.05);the pulmonary function of the observation group[vital capacity (VC),the ratio of forced respiratory volume to forced vital capacity (FEV1/FVC),Maximum ventilation (MVV)]was higher than that of the control group (P<0.05).Conclusion:Bosentan treatment can improve cardiopulmonary function and cardiac tolerance for patients with moderate to severe PAH after interventional treatment of CHD.

关 键 词：心脏缺损 先天性 高血压 肺性 西地那非 波生坦 每搏输出量 

分 类 号：R541.1[医药卫生—心血管疾病] R544.1[医药卫生—内科学]